INTRODUCTION
Alzheimer’s disease (AD) is characterized by a progressive decline of memory function and cognition. Hallmarks of AD pathology are extracellular aggregates of the amyloid β-peptide (Aβ), so-called amyloid plaques, and neurofibrillary tangles, which represent intraneuronal aggregates of hyperphosphorylated tau protein. The strongest correlate of the cognitive decline seen in AD, however, is the loss of synapses. 1-3 Moreover, there is mounting evidence for synaptic dysfunction and failure in AD both in vitro and in vivo (reviewed by Koffie et al. 4 and Selkoe 5). Oligomeric Aβ, as one of the key factors in AD, 6-7 is known to colocalize with dendritic spines—the main sites of synaptic input to excitatory pyramidal neurons—potentially binding to molecular components of the postsynaptic 8,9,10 and thereby exhibiting deleterious effects on dendritic spines. 4,7,11 This negative impact of Aβ on dendritic spines is most pronounced in close vicinity to amyloid plaques, causing an impairment of spine stability, which is thought to result in the loss of spines. 12-15 and ultimately synaptic connections. Previous in vivo imaging studies have largely focused on the impact of amyloid plaques on dendritic spines, 15,16 whereas not much is known about the presynaptic side, namely axonal boutons. In vivo. Histological studies, mostly using presynaptic markers, reported an overall decrease in synaptic density in AD patients, 1,2 whereas only a local reduction of presynaptic marker density close to plaques was observed in amyloid precursor protein (APP) transgenic mice. 17-19 Given the described effect of Aβ on the dynamics and density of dendritic spines, we hypothesized that these amyloid plaque-associated postsynaptic alterations should be paralleled by changes of the presynaptic compartment, either directly caused by the plaque itself or secondary to changes of spines. In the current study, we thus used in vivo two-photon imaging to follow dendritic spines and axonal boutons over the course of several weeks in wild-type (WT) and amyloid precursor protein/presenilin 1 (APPPS1) mice. We found an enhanced instability of both, pre- and postsynaptic structures, seen, for example, as a higher turnover rate and a lower survival fraction, limited to the immediate vicinity of plaques.

We then investigated whether these pathologically increased synaptic dynamics can be reduced or halted by treatment targeting Aβ generation. As Aβ is liberated upon sequential cleavage of APP by the β- and γ-secretase, 6,20 pharmacological inhibition of γ-secretase represents one way to interfere with Aβ generation. Although γ-secretase inhibitors (GSIs) have been shown to efficiently lower Aβ levels in the central nervous system (CNS) and reduce amyloid plaque load in animal models of the disease, 21,22 little is known about their potential to prevent plaque-associated synapse pathology.

We thus applied the novel, selective GSI (ELNS94) daily for 4 weeks, and monitored plaque progression and associated dendritic spine and axonal bouton pathology in APPPS1 mice. GSI treatment reduced de novo plaque formation after the first week of treatment, slowed down the growth of these newly deposited plaques and, importantly, stabilized spines near plaques by lowering their turnover rate and increasing their survival...
fraction. Likewise, GSI treatment normalized the survival fraction of boutons near plaques. Spines and boutons further away from plaques in APPPS1 mice and in WT mice were not affected by the GSI treatment.

MATERIALS AND METHODS

Animals for in vivo imaging experiments

For chronic in vivo imaging experiments, APPPS1 transgenic mice (co-expressing APP containing the Swedish double-mutation KM670/671NL and PS1 containing the L166P mutation under the Thy-1 promoter) were crossbred with green fluorescent protein (GFP)-M transgenic mice (expressing EGFP under the Thy-1 promoter, causing sparse labeling of mainly cortical layer V pyramidal neurons). Animals were kept under a 12/12 h light–dark cycle with food and water ad libitum and housed individually on standard cage bedding, without additional nesting material. All animal procedures followed a protocol approved by the local authorities (Regierung von Oberbayern). For imaging experiments, only male mice were used.

Drug administration

Male mice were treated with ELN594 (Elan Pharmaceuticals, South San Francisco, CA, USA) at the age of 3–4 months. The drug, dissolved in 2% methyl cellulose and 0.5% Tween20, was administered daily for four subsequent weeks via oral gavage at a dose of 30 mg kg



In vivo imaging

In brief, 4 weeks after implantation of a cranial window spanning both hemispheres (coordinates of craniotomy: Bregma +1.5 – 3.5 mm, 3 mm lateral from midline on each side) the apical tufts of GFP-expressing layer V pyramidal neurons and axonal boutons of layer II/III/V neurons, as well as amyloid plaques were repeatedly imaged at 7-day intervals. Amyloid plaques were stained by intraperitoneal injection of the dye Methoxy-XO4 (Neuoptix Corporation) 24 h prior to every imaging session.

Details on drug characterization, cranial window surgery, imaging, data analysis and statistics are provided in Supplementary Materials and Methods.

RESULTS

In order to characterize the impact of amyloid plaque pathology on the dynamics of synaptic structures in vivo, we performed longitudinal in vivo two-photon imaging in male WT and APPPS1 mice (Supplementary Figure S1). We then assessed whether pharmacological interference with Aβ generation exerts beneficial effects on plaque-associated synaptic pathology in APPPS1 mice. To this end, we administered the selective GSI, ELN594 (see Supplementary Results), daily (30 mg kg



Amyloid plaque-associated spine pathology

As there is accumulating evidence that plaques cause neuritic and spine pathology predominantly within 50 μm distance to plaques, we analyzed dendritic spines on apical tufts of layer V pyramidal neurons in WT (Figure 1a) and APPPS1 mice in the immediate vicinity of plaques (<50 μm, ‘near’; Figure 1b) and further away (>50 μm, ‘distant’). As described before (for review see Liebscher and Meyer-Luehmann), we found that dendritic stretches within the immediate vicinity of amyloid plaques exhibited a lower spine density (average over all time points 0.22 ± 0.017 μm



Amyloid plaque-associated axonal bouton pathology

Not much is known about the dynamics of plaque-associated presynaptic structures. We therefore analyzed axonal boutons located within the same imaged volumes as the above described dendrites. We took advantage of the fact that bouton dynamics were described in detail for the GFP-AM mouse line in a recent publication. Based on this study and judged by bouton size as well as the number and length of axonal branches, the majority of axons investigated are putatively originating from layer II/III/V cells (Figures 2a and b). In addition to en passant boutons, which represented the majority of boutons, terminaux boutons were included in the analyses, as their fraction was low and did not differ significantly between groups (fraction terminaux boutons: WT 0.04 ± 0.065, APP distant 0.09 ± 0.12, APP near 0.076 ± 0.1, Kruskal–Wallis, P = 0.45).

We did not find a significant difference in bouton density between WT and APPPS1 mice (WT 0.12 ± 0.01 μm



Funding

This work was supported by the NIA (K08AG034885) and the University of California Merced (SEED-UCM).
Figure 1. Amyloid plaque-associated dendritic spine alterations. (a and b) Representative examples of apical dendritic stretches of layer V pyramidal neurons repeatedly imaged within layer I over the course of 4 weeks in wild-type (WT) and amyloid precursor protein/presenilin 1 (APPPS1) mice (shown are maximum projections). Note that the actual position of the dendritic stretch in panel b is just above the plaque, with the dendrite not passing through it. Open arrowhead: spine lost, filled arrowhead: spine gained. (c) Spine density is significantly lower in the vicinity of plaques in APPPS1 mice, compared with dendrites further away from plaques and WT mice, respectively (repeated measures analysis of variance (ANOVA); $P<0.001$ and $P<0.001$). (d) Survival fraction of spines near plaques is significantly decreased (repeated measures ANOVA, $P<0.001$). (e) Classification of spines with respect to their lifetime. Filled circles denote the presence of a spine at the respective time point, open circles correspond to the absence of a spine and half-filled circles denote a spine being either present or absent at the respective time point. (f) Dendrites near plaques have fewer persistent (one-way ANOVA, $P<0.01$ and $P<0.05$) and more transient spines compared with spines distant from plaques and in WT mice (one-way ANOVA, $P<0.001$ and $P<0.01$). (g) Spine turnover rates near plaques are significantly elevated compared with spines further away from plaques and WT mice, respectively (one-way ANOVA, $P<0.001$). (h and i) Increased turnover results from higher (h) elimination (one-way ANOVA, $P<0.001$ and $P<0.01$) and (i) formation rates (Kruskal–Wallis, $P<0.001$ and $P<0.05$). Data in panels g–i are average values over all imaging time points. WT: $n=16$ dendrites (four mice); APP distant: $n=21$ dendrites (five mice); APP near: $n=12$ dendrites (five mice). Values are mean ± s.e.m., scale bar 5 μm (b), *$P<0.05$, **$P<0.01$, ***$P<0.001$. 

© 2014 Macmillan Publishers Limited Molecular Psychiatry (2014), 937 – 946
inter-bouton distance did also not depend on plaque proximity (Supplementary Figure S4). However, similar to our data on dendritic spines near plaques, further away from plaques or in WT mice (repeated measures ANOVA, $P = 0.93$). (d) Boutons near plaques exhibit a lower survival fraction (repeated measures ANOVA, $P < 0.01$). (e) Bouton lifetime categories (see Figure 1e) do not differ significantly among groups (fraction persistent boutons: one-way ANOVA, $P = 0.12$, fraction transient: Kruskal–Wallis $P = 0.31$, fraction persistent lost: Kruskal–Wallis $P = 0.63$, fraction persistent gained: Kruskal–Wallis $P = 0.61$). (f) Turnover rate is increased on boutons close to plaques (Kruskal–Wallis, $P < 0.05$). Separate analysis of (g) elimination and (h) formation rate showed the same trend but did not reach significance (Kruskal–Wallis, $P = 0.23$ and $P = 0.24$). WT: $n = 17$ axons (four mice); APP distant: $n = 14$ axons (four mice); APP near: $n = 13$ axons (four mice). Values are mean ± s.e.m., scale bar $10 \mu m$ (b), *$P < 0.05$, **$P < 0.01$.

Figure 2. Bouton dynamics in wild-type (WT) and amyloid precursor protein/presenilin 1 (APPPS1) mice. (a and b) Examples of axonal stretches in (a) WT and (b) APPPS1 mice over the 4-week-imaging period are shown as maximum projections. Boutons lost from one time point to the next are marked with open arrowheads, boutons gained with filled arrowheads. (c) Bouton density is not different between axons near plaques, further away from plaques or in WT mice (repeated measures ANOVA, $P = 0.93$). Overall, boutons appeared less dynamic than spines on apical tufts of layer V neurons, corroborating earlier reports.30,33 Newly formed spines have been shown to preferentially target large multisynaptic boutons,34 which could account for the observed difference.

Apart from the above mentioned changes in bouton dynamics, we occasionally observed the emergence of axonal dystrophies, axonal breakage and axonal sprouting within the peri-plaque region (Supplementary Figure S5). These structural alterations
occurred only rarely in APPPS1-GFP mice, probably attributable to the young age of 3–4 months and the sparse labeling of neurons in the GFP-M mouse line.

Initial reduction in de novo plaque deposition by GSI treatment
We next investigated whether the enhanced dynamics of synaptic structures near amyloid plaques can be halted by Aβ-targeting treatment. For this purpose, we tested the sulfonamide-type GSI ELN594 both in WT and APPPS1 mice.

ELN594 is an orally available, CNS penetrant and highly potent GSI (see Supplementary Results, Supplementary Figures S6a–c). As PS1 mutations of familial AD, such as the aggressive PS1L166P mutation present in the mouse model used here, are known to be less sensitive to GSIs, we first tested the effect of a single dose of ELN594 (30 mg kg\(^{-1}\)) on APP C-terminal fragments as well as Aβ40 and Aβ42 levels in brains of APPPS1-GFP mice 24 h after drug application. The GSI efficiently inhibited γ-secretase as shown by the pronounced accumulation of APP C-terminal fragments in the western blot analysis (219% compared with vehicle-treated animals, Figures 3a and b). In accordance with the observed increase in APP C-terminal fragment levels, we found that soluble Aβ40 and Aβ42 levels were significantly decreased by 66% and 59%, respectively, upon GSI application, indicating that GSI treatment efficiently lowers Aβ levels in the APPPS1 mouse model (Figure 3c). We hence determined integrated spine brightness as a measure of spine formation, manifested as a drop in the number and size of newly deposited plaques in GSI-treated APPPS1 mice compared with vehicle-treated mice after the first week of GSI treatment (Figures 3f and g). The observed decrease in newly formed plaques after 1 week of treatment ceased over the course of the experiment, and a general decline in the occurrence of new plaques was seen in both GSI-treated and control mice, which might reflect the age dependency of plaque deposition (Figure 3f). However, plaques newly formed within the first week of treatment grew significantly slower in GSI compared with vehicle-treated mice, indicating a sustained effect of the GSI throughout the treatment period (Figure 3h).

Effect of GSI treatment on plaque-associated spine and bouton alterations
We applied the GSI to APPPS1 mice daily for 4 consecutive weeks. WT mice were treated in addition in order to test for potential adverse effects of the treatment that have been described in a previous publication for unselctive GSIs of a different structural class.37 GSI treatment had neither an effect on spine density in APPPS1 (Figures 4a and b) nor on those in WT mice (Supplementary Figure S7a) over the course of the 4-week treatment period.

Importantly, GSI treatment counteracted the plaque-associated changes in spine dynamics. More specifically, in GSI-treated mice we observed a higher spine survival fraction near plaques (Figure 4c), a higher fraction of persistent spines (Figure 4d) and accordingly a lower fraction of transient spines (Figure 4d) compared with spines near plaques in vehicle-treated mice. The pathologically enhanced elimination and formation rates of spines near plaques in vehicle-treated mice were reduced by the GSI to levels found on dendrites further away from plaques (Figures 4e–g). Note that presented here are average values over all time points, as spine dynamics were consistently elevated throughout the treatment period (see Supplementary Figures S8a–c).

As the density of spines within a radius of 50 μm to the plaque edge correlates well with the effective plaque distance (Supplementary Figure S2a), we investigated whether GSI treatment affects spines in a distance-dependent manner. Whereas the GSI had no effect on spine density near plaques at any given distance between 0 and 50 μm, the turnover rate was significantly reduced for spines that were >15 μm (yet <50 μm) away from the plaque border (Supplementary Figures S9a–d).

In addition to alterations in synapse number and turnover, pathology might also be reflected in changes to the strength of a synapse, which is known to correlate well with spine size.43,44,45 We hence determined integrated spine brightness as a measure for spine size.41 In line with a previous report,40 the overall distribution of spine sizes resembled a log-normal distribution, both for spines close to plaques in APP and WT mice (Supplementary Figures S10a–c). Average spine size as well as spine-size distribution did not differ between treatment groups (Supplementary Figures S10b–d).

As stable spines are considered the structural correlates of long-term memories,41,42 we next performed the same analysis separately for persistent spines. We determined their size difference between the first and the last imaging time point (Supplementary Figure S10e). In line with our findings of higher spine turnover rates in the vicinity of plaques, we observed a significantly higher fraction of persistent spines with a large size change (difference in integrated brightness larger than the mean difference ±1.5×s.d. of persistent spine-size changes in WT vehicle-treated mice) close to plaques (WT vehicle 15.4% versus APP near vehicle 27.7%, Supplementary Figure S10f). GSI treatment led to a reduction in this ‘large size change fraction’ of persistent spines (20.1%), which did not significantly differ anymore from WT vehicle mice (Supplementary Figure S10f).

GSI treatment did not affect spines further away from plaques and in WT mice (for data on WT mice, see Supplementary Figures S7a–d), indicating no obvious neuropathological side effect of the GSI treatment.

Owing to the high variability, it was more difficult to pinpoint the impact of the GSI on bouton dynamics (Figure 5a), but overall we found the same trend as for dendritic spines. Bouton density was not significantly affected by the GSI treatment, yet a trend towards a decrease throughout the imaging period was observed near plaques in vehicle-treated mice (Figure 5b). These findings notwithstanding, we did observe a normalization of the bouton survival fraction near plaques to levels found distant from plaques (Figure 5c). The significantly elevated bouton turnover rate near plaques was somewhat decreased by the GSI; however, the effect did not reach significance (Figure 5d). The same held true for the fraction of persistent boutons near plaques, where we observed a nonsignificant increase after the GSI treatment (one-way ANOVA, \(P = 0.22\), Figure 5e).

In summary, our data demonstrate that the dynamics of both the pre- and postsynaptic compartments is affected by the amyloid plaque pathology. Moreover, we found that interference with Aβ generation by applying the GSI, ELN594, can attenuate the plaque-associated instability of synaptic structures. ELN594 does neither affect spines or boutons further away from plaques in APPPS1 nor those in WT mice, and hence seems to be devoid of apparent neuropathological side effects.

DISCUSSION
In this study, we have used a longitudinal in vivo two-photon imaging approach to characterize plaque-associated alterations of pre- and postsynaptic structures in a mouse model of AD. We demonstrate that interference with Aβ generation, via the application of a novel GSI, can counteract the plaque-associated synaptic instability in vivo.

There is growing consensus that, for a treatment against AD to be effective, it should commence already during the presymptomatic phase of the disease.33 A number of studies performed in APP-transgenic mice have revealed an intimate relationship between amyloid plaques and structural-functional neuronal

© 2014 Macmillan Publishers Limited

Molecular Psychiatry (2014), 937 – 946
alterations.\textsuperscript{12–15,26,44} As these structural alterations are considered a precursor to eventual neuronal death, characteristic for human AD pathology,\textsuperscript{45} mouse models are well suited to study the efficacy of candidate drugs on these early neuropathological changes.

Our results, similar to previous publications,\textsuperscript{12,15,16} show a lower spine density and a pronounced spine instability within the immediate vicinity of amyloid plaques. The observed increase in spine turnover was attributable to almost equally enhanced spine formation and elimination rates, thereby not resulting in a change of spine density over the course of the 4-week-imaging period. Thus, the lowered spine density observed near mature plaques must result from a net spine loss at an earlier time point, probably following initial plaque formation, after which spine density stabilized again. This interpretation is supported by a recent study in an APPPS1 mouse model, which showed that plaque deposition precedes spine loss, and also found that even in aged APPPS1 mice, which already bear a substantial plaque load, spine density in the vicinity of plaques does not differ from that seen in young animals near plaques.\textsuperscript{16}

Close to plaques, not only spine turnover was increased, but we also found that particularly persistent spines, which are thought to encode long-term memories,\textsuperscript{41,42} varied more strongly in size over time. As spine size correlates with synapse strength,\textsuperscript{34,38,39} this indicates that both, alterations in spine turnover as well as fluctuations in spine size, conversely increase synaptic instability close to plaques.

Notably, despite the fact that, on average, spines distant from plaques did not behave differently from spines in WT mice, we found evidence of altered structural plasticity independent of

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{\textit{\textsuperscript{3}secrate inhibitor (GSI) treatment reduces A\textsubscript{beta} generation in vivo and attenuates the deposition and growth of new plaques in amyloid precursor protein/presenilin 1 (APPPS1) mice.} (a) Representative western blot analysis of the effect of GSI application on full length amyloid precursor protein (fl-APP) and APP C-terminal fragment (APP-CTF) levels in APPPS1 brain homogenates (blots of two different experiments are shown). (b) Quantification of GSI effect on APP-CTFs normalized to fl-APP as measured in western blot (t-test, $P = 0.0002$). (c) Quantification of ELISA analysis of soluble A\textsubscript{beta} species (A\textsubscript{beta}40 decreased by 66\%, t-test, $P = 0.036$ and A\textsubscript{beta}42 decreased by 59\%, t-test, $P = 0.023$, vehicle $n = 4$, GSI $n = 3$ mice); open circles represent single data points, horizontal bars denote the mean and gray boxes the s.e.m. (d and e) Examples of \textit{in vivo} two-photon images in APPPS1 mice treated daily with vehicle (d) and 30 mg kg\textsuperscript{-1} GSI (e), respectively. Images are maximum projections of 50 optical sections (z-spacing 5 \textmu m) over a depth of 250 \textmu m. Red arrowheads indicate newly formed plaques, which are marked with white arrowheads at consecutive imaging time points. (f) Number of newly emerged plaques per standard ROI (350 x 350 x 285 \textmu m) are lower in GSI-treated mice after the first week: one-sided Mann–Whitney test, $P = 0.027$, values are mean ± s.e.m. (g) Plaques newly formed within the first week of treatment are significantly smaller in GSI-treated mice (one-sided Mann–Whitney test, $P = 0.014$); black lines denote the mean. (h) Newly formed plaques grow significantly slower in GSI compared with vehicle-treated mice; values are median ± 95\% confidence interval of the median (repeated measures ANOVA, $P = 0.014$; APP vehicle: 22 ROIs (five mice), 45 new plaques after first week; APP GSI: 27 ROIs (seven mice), 31 new plaques after first week). Scale bar 20 \textmu m, *$P < 0.05$, ***$P < 0.001$.}
\end{figure}
plaque pathology. Whereas in WT mice spine density was negatively correlated with spine turnover rate, as reported previously, in APPPS1 mice dendrites further away from plaques exhibited a positive correlation between spine density and turnover rate. A more detailed analysis revealed that this difference between genotypes was largely due to a reduced spine turnover on low-density stretches in APPPS1 mice. The reduction in spine dynamics on dendrites distant from plaques may indicate a weakening of synaptic efficacy. The induction of long-term potentiation (LTP) on individual spines can promote the potentiation of synapses on neighboring spines and the formation of new adjacent spines, an effect known to spread over several micrometers along the dendrite. In APP-transgenic mice, soluble Aβ is elevated within the interstitial fluid and is known to disrupt LTP induction and alter synapse composition. This negative impact of Aβ might impede synaptic cooperativity, most prominently on dendrites bearing only a few inputs, as their combined synaptic drive, and hence the potential for 'cross-talk' between neighboring spines should be lower even under physiological conditions.

In concert with the increased turnover rate of spines near plaques, we also found that axonal boutons close to plaques were less stable. In contrast to spine density, however, bouton density did not change with plaque distance. Whereas this seems to be at odds with histological studies showing a loss of presynaptic markers close to plaques, the latter result likely reflects the joint loss of axons and their boutons, while we measure bouton density on those axons still present close to plaques. Alternatively, the vulnerability of axonal boutons to Aβ/amyloid plaques may be cell type-specific. We have confined our analysis to intracortical axons of layer II/III/V neurons, which have a lower bouton density and are more stable compared with, for example, the axons of layer VI cells.

The pathologically elevated dynamics of spines and boutons is very likely to affect synaptic plasticity, and hence memory formation, retention and retrieval, in a similar manner as the loss of synapses. Recent imaging studies have shown that the formation of long-term memories tightly correlates with the emergence of long-lived spines in the cortex. On the other hand, inherited forms of mental retardation, such as the fragile X-syndrome, are associated with high spine turnover rates, as observed in Fmr1 knockout mice. Moreover, altered dynamics of pre- and postsynaptic structures in the cortex have recently been shown to accompany normal aging
and hence were suggested to underlie age-related cognitive deficits. Our finding of enhanced dynamics of synaptic structures close to plaques resembles these changes observed during normal ageing, alluding to potentially similar cellular mechanisms causing the cognitive deficits during normal aging and AD. Together, these findings stress the causal relevance of altered spine and bouton dynamics for neurodegenerative diseases and, furthermore, imply that the impact of synaptic instability on the cognitive decline seen in AD might have been underestimated thus far.

The molecular mechanisms underlying the enhanced turnover of synaptic structures close to plaques resemble these changes observed during normal ageing, alluding to potentially similar cellular mechanisms causing the cognitive deficits during normal aging and AD. Together, these findings stress the causal relevance of altered spine and bouton dynamics for neurodegenerative diseases and, furthermore, imply that the impact of synaptic instability on the cognitive decline seen in AD might have been underestimated thus far.

The molecular mechanisms underlying the enhanced turnover of synaptic structures close to plaques are not well understood. Plaques are considered a reservoir of soluble Aβ that seems to extend with a gradient beyond the histological border of the dense core plaque. This locally elevated concentration of soluble Aβ in the plaque region might cause the structural and functional alterations predominantly seen in the vicinity of plaques, such as dysmorphic neurites, changes in spine stability and spine density, as well as the occurrence of clusters of hyperactive cells and Ca2+-overloaded dendrites. Spines on Ca2+-overloaded dendrites lack functional compartmentalization, a property considered a prerequisite for synaptic integration. The breakdown of spine compartmentalization in a subset of dendrites near plaques might account for the observed spine instability.

In addition to plaques, other pathological events associated with AD also affect synaptic structures. A recent in vivo imaging study performed in triple transgenic AD mice (bearing in addition to the APPswe and PS1M146V also the Tau P301L mutation) suggests that intraneuronal hyperphosphorylated tau can have a strong impact on spine density as well. The authors describe spine loss on dystrophic dendrites positive for hyperphosphorylated tau in brain areas that were devoid of plaques.
Furthermore, in areas with substantial plaque load, spine density was found to be lower even distant from plaques (>50 μm).

Having found that amyloid plaques cause local synaptic instability, we next tested whether Aβ-targeting treatment can exert beneficial effects on this pathology. At the concentration used, the GSI, ELN594, inhibited γ-secretase effectively, reducing Aβ generation in APPPS1 mice to levels comparable to those observed with other GSIs in different APP-transgenic mice.21,22,61 We found that the lowered Aβ levels caused an initial attenuation of new plaque deposition and a sustained diminished growth of the newly formed plaques throughout the treatment period, in line with a previous report showing that GSI treatment can suppress the formation of new plaques.21 The observed overall decline in the number of newly formed plaques in the treatment and control group might reflect the age dependency of de novo plaque formation60 or could be attributable to the anti-amyloidogenic properties of Methoxy-XO4,64 which we applied repeatedly in order to label plaques in vivo. However, both the vehicle- and the GSI-treated groups should be affected equally by Methoxy-XO4, thus essentially resulting in a potential underestimation of the GSI effect on plaque formation. The moderate GSI effect on plaque pathology was accompanied by a substantial impact on synaptic structures in the vicinity of plaques. GSI treatment specifically reduced the plaque-associated spine instability, resulting in spine turnover rates comparable to those found in regions distal to plaques. Similarly, the GSI reduced the increased size fluctuations of persistent spines close to plaques. Intriguingly, a more detailed analysis of the ‘near plaque’ spine cohort (<50 μm away) revealed that GSI treatment normalized, in particular, the dynamics of spines located >15 μm away from the plaque border. As soluble Aβ levels gradually fall off next to dense core plaques,10 we propose that the synapse-stabilizing effect of ELN594 occurs in a threshold-dependent manner. We assume that the lower concentrations of Aβ at the periphery of the plaque-surrounding halo is cleared more rapidly once additional Aβ generation is inhibited via the GSI, and as a consequence synaptic structures located there recover from elevated turnover more readily than those still in tight contact with the dense core plaque and higher Aβ levels.

In a recent two-photon imaging study, GSI treatment was shown to restore the pathologically enhanced neuronal activity levels in hippocampal CA1 neurons in predepositing APP-transgenic mice.65 In depositing mice, however, hyperactive cells are exclusively found within the vicinity of plaques both in the hippocampus and the cortex.44,65 It remains to be clarified whether GSI treatment in depositing mice can prevent this neuronal dysfunction in an equally effective manner as observed in predepositing mice,66 which then would suggest a link between our finding of GSI-induced synapse stabilization and the normalization of neuronal-activity patterns near plaques. We did not observe any effect of the GSI on dendrites distant from plaques in APPPS1 mice nor on spines in WT mice. This is at odds with a recently published study, which reported a GSI-induced rapid and prolonged decrease in spine density in WT mice within a short treatment period of 4 days.27 Earlier observation GSIs are known to non-selectively interfere with the processing of other γ-secretase substrates. In particular, impaired cleavage of Notch, a cell-surface receptor involved in cell differentiation and development,26 is thought to cause side effects of GSI treatment. The inhibitors used in the above mentioned study, DAPT and LY450139 (semagacestat), are unselective GSIs (ratio of EC_{50} values for Notch and Aβ42: DAPT = 0.5; LY450139 = 0.8)26 and belong to a different structural class than the second-generation compound ELN594, a sulfonamide-type GSI with an at least 10-fold higher selectivity of APP over Notch substrate cleavage (data not shown). The previously investigated compounds might also substantially differ in their pharmacokinetic and pharmacologic properties, factors, which may further contribute to a different side effect profile. It is also conceivable that the compounds used in the previous study might have had off-target effects. Chronic administration of ELN594 on the other hand did not affect dendritic spines or axonal boutons in WT mice or APPPS1 mice distant from plaques and hence seems to be devoid of those aforementioned side effects.

Taken together, we here for the first time demonstrate in vivo the ability of a GSI to selectively alleviate plaque-associated synaptic pathology in a mouse model of AD. Given that the impact of plaques on the density of spines has been shown in various brain regions, such as neocortex and hippocampus,12,14–16 we believe that the plaque-associated enhanced dynamics of synaptic structures represents a general mechanism by which plaques convey their detrimental effects on synapses. Thus, the GSI effect on synapses should pertain to other brain regions as well. Our data, moreover, argue in favor of the amyloid cascade hypothesis and serve as a proof of principle regarding the efficacy of pharmacological interference with Aβ generation.

CONFLICT OF INTEREST
KQ, EG, EFB, DO, GS, DBS either were, or currently still are, employees of Elan Pharmaceuticals. at the time the studies reported in this manuscript were being conducted, hold (or held) stock in Elan and are inventors on patent filings resulting from the work described herein. CH has acted as a consultant for Elan Pharmaceuticals. All other authors declare no conflict of interests.

ACKNOWLEDGMENTS
We would like to thank Victoria Milde, Claudia Abou-Ajam and Claudia Huber for their help with data analysis and technical assistance. We also thank Mathias Jucker for providing the APPPS1 mice. This work was supported by the Emmy Noether Program of the DFG (MM-L), the SFB 596 ‘Molecular Mechanisms of Neurodegeneration’ of the DFG (CH, HS), the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007–2013)/ERC Grant Agreement No. 231366 Amlyoid (advanced grant to CH), the KND0 of the BMBF (CH, HS), the Center for Integrated Protein Science Munich, Hans and Ilse Breuer Foundation (MM-L), the Graduate School of Systemic Neurosciences (SL), the International Max Planck Research School (SL) and the Max Planck Society (SL, TB, MH). CH is supported by a research professorship by the LMUexcellent program.

REFERENCES
1. Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA. Cortical and subcortical patterns of synaptophysin-like immunoreactivity in Alzheimer’s disease. Am J Pathol 1991; 138: 235–246.
2. Terry RD et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572–580.
3. Scheff SW, Price DA. Alzheimer’s disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 2006; 9(3 Suppl): 101–115.
4. Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer’s disease: synapse loss is the major cause of cognitive impairment. Nat Rev Neurol 2011; 9(3): 945.
13. Spires TL et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravitreal multiphoton microscopy. J Neurosci 2005; 25: 7276–7287.

14. Gruutzendler J, Helmink K, Tsai J, Gan WB. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer’s disease. Ann N Y Acad Sci 2007; 1097: 30–39.

15. Tsai J, Gruutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakdown of neuronal branches. Nat Neurosci 2004; 7: 1181–1183.

16. Bittner T et al. Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathol 2012; 124: 797–807.

17. King DL, Arendash GW. Maintained synaptophosphin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment. Brain Res 2002; 926: 58–68.

18. Bonci P et al. Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol Aging 2005; 26: 607–613.

19. Dong H, Martin MV, Chambers S, Csemansky JG. Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. J Comp Neurol 2007; 508: 311–321.

20. Steiner H, Fluhrer R, Haass C. Intramembrane proteolysis by gamma-secretase. J Biol Chem 2008; 283: 29267–29263.

21. Yan P et al. Characterizing the appearance and growth of amyloid plaques in APP/ PS1 mice. J Neurosci 2009; 29: 10706–10714.

22. Best JD et al. The novel gamma secretase inhibitor N-cis-4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 2007; 320: 552–558.

23. Radde R et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006; 7: 940–946.

24. Feng G et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2006; 28: 41–51.

25. Truong AP et al. Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors. Bioorg Med Chem Lett 2009; 19: 4920–4923.

26. Meyer-Luehmann M et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature 2008; 451: 720–724.

27. Kuchihota KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. Amyloid plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2006; 50: 214–225.

28. Liebscher S, Meyer-Luehmann MA. Peepholes into the brain: neuropathological features of Alzheimer’s disease revealed by in vivo two-photon imaging. Front Psychiatry 2012; 3: 26.

29. Trachtenberg JT et al. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature 2002; 420: 788–794.

30. Holtmaat AJ et al. Transient and persistent dendritic spines in the neocortex in vivo. Neuron 2005; 45: 279–291.

31. Hofer SB, Mrsic-Flogel TD, Bonhoeffer T, Hubener M. Experience leaves a lasting effect on Abeta42 production. Proc Natl Acad Sci USA 2011; 108; 10706–10714.

32. Shankar GM et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837–842.

33. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192: 106–113.

34. Cruz-Martín A, Crespo M, Portera-Caillau C. Delayed stabilization of dendritic spines in fragile X mice. J Neurosci 2010; 30: 7793–7803.

35. Grillo FW et al. Increased axonal bouton dynamics in the aging mouse cortex. Proc Natl Acad Sci USA 2013; 110; E1514–E1523.

36. Mustany R, Anstey JE, Crump KL, Maco B, Knott G, Portera-Caillau C. Altered synaptic dynamics during normal brain aging. J Neurosci 2013; 33: 4094–4104.

37. Grunditz A, Holbro N, Tian L, Zuo Y, Oertner TG. Spine neck plasticity controls and growth in a mouse model of cerebral beta-amyloidosis. Proc Natl Acad Sci USA 2013; 110; 58–68.

38. Harris KM, Stevens JK. Dendritic spines of CA1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics. J Neurosci 1989; 9: 2982–2997.